PE20010040A1 - Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona - Google Patents

Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona

Info

Publication number
PE20010040A1
PE20010040A1 PE2000000364A PE0003642000A PE20010040A1 PE 20010040 A1 PE20010040 A1 PE 20010040A1 PE 2000000364 A PE2000000364 A PE 2000000364A PE 0003642000 A PE0003642000 A PE 0003642000A PE 20010040 A1 PE20010040 A1 PE 20010040A1
Authority
PE
Peru
Prior art keywords
maleic acid
diona
pyridyl
benzyl
amino
Prior art date
Application number
PE2000000364A
Other languages
English (en)
Inventor
Robert Gordon Giles
Michael John Sasse
Paul David James Blackler
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20010040A1 publication Critical patent/PE20010040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA POLIMORFICA DE LA SAL DEL ACIDO MALEICO DE 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]-TIAZOLIDINA-2,4-DIONA, EN FORMA AISLADA, PURA, CRISTALINA CARACTERIZADA POR EL ESPECTRO INFRARROJO, ESPECTRO RAMAN, ESPECTRO DE RESONANCIA MAGNETICA NUCLEAR EN ESTADO SOLIDO, PATRON DE DIFRACCION DE RAYOS X. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION CARACTERIZADO POR: a)CALENTAR LA SUSPENSION LECHOSA DE LA SAL DEL ACIDO MALEICO DE 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]-TIAZOLIDINA-2,4-DIONA EN ETANOL ACUOSO QUE CONTIENEN HASTA ALREDEDOR 2,5% P/V DE AGUA, DURANTE UN PERIODO DE TIEMPO PROLONGADO, DESPUES SE RECUPERA EL POLIMORFO DEL ETANOL DESNATURALIZADO; b) EL COMPUESTO SE MEZCLA CON ETANOL DESNATURALIZADO Y SE CALIENTA A TEMPERATURA ELEVADA POR UN PERIODO DE TIEMPO PROLONGADO LUEGO SE RECUPERA EL POLIMORFO DEL DISOLVENTE; c) SE SIEMBRA EL COMPUESTO EN ETANOL DESNATURALIZADO QUE CONTIENE HASTA 2,5% P/V DE AGUA, A 55°C CON EL POLIMORFO, SE ENFRIA DE 20°C A 25°C. EL COMPUESTO DE LA SAL DEL ACIDO MALEICO ES UTIL EN EL TRATAMIENTO DE DIABETES MELLITUS
PE2000000364A 1999-04-23 2000-04-19 Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona PE20010040A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
PE20010040A1 true PE20010040A1 (es) 2001-03-10

Family

ID=26315460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000364A PE20010040A1 (es) 1999-04-23 2000-04-19 Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona

Country Status (40)

Country Link
US (2) US6815457B1 (es)
EP (3) EP1903043A1 (es)
JP (1) JP2002543075A (es)
KR (1) KR100744359B1 (es)
CN (1) CN1208335C (es)
AP (1) AP1495A (es)
AR (2) AR023564A1 (es)
AT (2) ATE382046T1 (es)
AU (1) AU765498B2 (es)
BG (1) BG65427B1 (es)
BR (1) BR0009934A (es)
CA (1) CA2370258A1 (es)
CO (1) CO5170424A1 (es)
CY (1) CY1107238T1 (es)
CZ (1) CZ20013799A3 (es)
DE (2) DE60004658T2 (es)
DK (2) DK1173434T3 (es)
DZ (1) DZ3155A1 (es)
EA (1) EA004534B1 (es)
ES (2) ES2298327T3 (es)
HK (2) HK1045154B (es)
HR (1) HRP20010773B1 (es)
HU (1) HUP0200929A3 (es)
IL (1) IL146110A0 (es)
MA (1) MA26785A1 (es)
MX (1) MXPA01010820A (es)
MY (1) MY128007A (es)
NO (1) NO320589B1 (es)
NZ (1) NZ515163A (es)
OA (1) OA11871A (es)
PE (1) PE20010040A1 (es)
PL (1) PL351686A1 (es)
PT (2) PT1284268E (es)
RS (1) RS50114B (es)
SK (1) SK286423B6 (es)
TR (1) TR200103061T2 (es)
TW (1) TW591027B (es)
UA (1) UA67843C2 (es)
UY (1) UY26120A1 (es)
WO (1) WO2000064892A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
DK1173434T3 (da) 1999-04-23 2003-12-08 Smithkline Beecham Plc Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
IL155036A0 (en) * 2000-09-26 2003-10-31 Reddy Research Foundation Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
SG47100A1 (en) 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
KR20010013845A (ko) 1997-06-18 2001-02-26 피터 기딩스 티아졸리딘디온 및 알파-글루코시다제 억제제를 사용한당뇨병의 치료
WO1998057649A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
PE20010044A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
DK1173434T3 (da) 1999-04-23 2003-12-08 Smithkline Beecham Plc Thiazolidindionderivat og dets anvendelse som antidiabetisk middel
WO2000064893A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
IL155036A0 (en) 2000-09-26 2003-10-31 Reddy Research Foundation Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
NO20015149D0 (no) 2001-10-22
CA2370258A1 (en) 2000-11-02
WO2000064892A3 (en) 2001-01-25
AR023568A1 (es) 2002-09-04
BG106119A (en) 2002-05-31
OA11871A (en) 2006-03-27
KR20020028873A (ko) 2002-04-17
HK1045154A1 (en) 2002-11-15
CY1107238T1 (el) 2012-11-21
NZ515163A (en) 2004-02-27
DZ3155A1 (fr) 2000-11-02
ES2204557T3 (es) 2004-05-01
RS50114B (sr) 2009-03-25
DE60037602D1 (de) 2008-02-07
DK1173434T3 (da) 2003-12-08
MA26785A1 (fr) 2004-12-20
AP1495A (en) 2005-11-30
EP1284268B1 (en) 2007-12-26
TW591027B (en) 2004-06-11
BR0009934A (pt) 2002-06-04
US6815457B1 (en) 2004-11-09
SK286423B6 (sk) 2008-09-05
US20040092555A1 (en) 2004-05-13
WO2000064892A2 (en) 2000-11-02
SK14912001A3 (sk) 2002-02-05
PT1173434E (pt) 2003-12-31
HK1055293A1 (en) 2004-01-02
PL351686A1 (en) 2003-06-02
HUP0200929A2 (en) 2002-08-28
CN1355801A (zh) 2002-06-26
DE60037602T2 (de) 2009-01-08
HRP20010773A2 (en) 2002-10-31
CZ20013799A3 (cs) 2002-04-17
DK1284268T3 (da) 2008-04-28
EP1284268A1 (en) 2003-02-19
UY26120A1 (es) 2000-12-29
CO5170424A1 (es) 2002-06-27
JP2002543075A (ja) 2002-12-17
CN1208335C (zh) 2005-06-29
EP1173434B1 (en) 2003-08-20
DE60004658D1 (de) 2003-09-25
ATE382046T1 (de) 2008-01-15
AR023564A1 (es) 2002-09-04
EA004534B1 (ru) 2004-06-24
MXPA01010820A (es) 2002-06-04
AU4130600A (en) 2000-11-10
PT1284268E (pt) 2008-03-10
ES2298327T3 (es) 2008-05-16
IL146110A0 (en) 2002-07-25
EP1903043A1 (en) 2008-03-26
HUP0200929A3 (en) 2004-03-29
EA200101119A1 (ru) 2002-04-25
YU75201A (sh) 2004-09-03
TR200103061T2 (tr) 2002-05-21
ATE247653T1 (de) 2003-09-15
KR100744359B1 (ko) 2007-07-30
NO20015149L (no) 2001-12-17
EP1173434A2 (en) 2002-01-23
NO320589B1 (no) 2005-12-27
AU765498B2 (en) 2003-09-18
UA67843C2 (uk) 2004-07-15
HK1045154B (zh) 2004-06-25
HRP20010773B1 (en) 2005-06-30
BG65427B1 (bg) 2008-07-31
DE60004658T2 (de) 2004-06-24
MY128007A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
PE20010040A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
PE20010044A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
ES2371786T3 (es) Polimorfo de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolocarboxílico y método para su preparación.
KR101052122B1 (ko) 아미노디히드로티아진 유도체
PE20000125A1 (es) Hidrato de la sal de acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
PE20010045A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
JP2007169288A (ja) レボフロキサシンおよびその形態の調製
ES2259725T3 (es) Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion.
AR017214A1 (es) Un proceso para preparar un hidrato de la sal del acido maleico de 5-[4[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona
WO2004104010A1 (en) Crystalline form of cefdinir
JPS6020394B2 (ja) 抗生物質の製造方法
US20220025254A1 (en) Complexes and Ligands
AR023567A1 (es) Un procedimiento para preparar un monohidrato de hidrocloruro derivado de la tiazolidin-2,4-diona
AU623942B2 (en) Thiazole derivatives
ES2253315T3 (es) Analogos de fenoxacina para el tratamiento de amiloides.
ES2272528T3 (es) Un derivado de tiazolidindiona y su uso como antidiabetico.
JPH06293746A (ja) （アルコキシシアノフェニル）チアゾール誘導体の製造方法
JP2572563B2 (ja) セファロスポリン中間生成物の新規安定な結晶形
JPH01502026A (ja) 抗潰瘍作用を有する化合物の製法
Kumar et al. synthesis of some novel thiazolidin-4-one substituted 1, 2, 4-triazoles of their antimicrobial activity studies
AU2020309946A1 (en) Method for producing insulin-producing cell using dihydroindolizinone derivatives
JPH10120681A (ja) 新規アザインドール化合物
JPH1045735A (ja) ベンゾチアゾール及びベンゾオキサゾール誘導体の製法
JPH10316678A (ja) チアゾリルベンゾフラン誘導体の製造方法
ECSP982781A (es) Hidrato de la sal de maleico de 5-[4- (-n -metil-n- (2-piridil) amino) etoxi) bensil) tiazolidina - 2,4 diona

Legal Events

Date Code Title Description
FC Refusal